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Surveillance of antimicrobial resistance (AMR) in non-typhoidal Salmonella enterica
(NTS), is essential for monitoring transmission of resistance from the food chain to
humans, and for establishing effective treatment protocols. We evaluated the prediction
of phenotypic resistance in NTS from genotypic profiles derived from whole genome
sequencing (WGS). Genes and chromosomal mutations responsible for phenotypic
resistance were sought in WGS data from 3,491 NTS isolates received by Public Health
England’s Gastrointestinal Bacteria Reference Unit between April 2014 and March
2015. Inferred genotypic AMR profiles were compared with phenotypic susceptibilities
determined for fifteen antimicrobials using EUCAST guidelines. Discrepancies between
phenotypic and genotypic profiles for one or more antimicrobials were detected for 76
isolates (2.18%) although only 88/52,365 (0.17%) isolate/antimicrobial combinations
were discordant. Of the discrepant results, the largest number were associated with
streptomycin (67.05%, n = 59). Pan-susceptibility was observed in 2,190 isolates
(62.73%). Overall, resistance to tetracyclines was most common (26.27% of isolates,
n = 917) followed by sulphonamides (23.72%, n = 828) and ampicillin (21.43%, n = 748).
Multidrug resistance (MDR), i.e., resistance to three or more antimicrobial classes,
was detected in 848 isolates (24.29%) with resistance to ampicillin, streptomycin,
sulphonamides and tetracyclines being the most common MDR profile (n = 231;
27.24%). For isolates with this profile, all but one were S. Typhimurium and 94.81%
(n = 219) had the resistance determinants blaTEM−1, strA-strB, sul2 and tet(A).
Extended-spectrum β-lactamase genes were identified in 41 isolates (1.17%) and
multiple mutations in chromosomal genes associated with ciprofloxacin resistance in
82 isolates (2.35%). This study showed that WGS is suitable as a rapid means of
determining AMR patterns of NTS for public health surveillance.
Keywords: antimicrobial resistance, multidrug resistance, non-typhoidal Salmonella enterica, whole genome
sequencing, public health surveillance, One Health
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INTRODUCTION
Salmonella enterica subspecies enterica is responsible for 99%
of salmonellosis cases in humans and animals, and can be
further subdivided into the host-restricted typhoidal salmonellae
and the more generalist non-typhoidal salmonellae (NTS)
(Langridge et al., 2015; Wain et al., 2015). As host-adapted or
generalist organisms, NTS can be transferred from animals to
humans causing zoonotic infections and therefore fall under the
World Health Organization’s One Health approach. Globally,
NTS were estimated to cause 93.8 million enteric infections
resulting in 155,000 deaths annually (Majowicz et al., 2010),
and in the United Kingdom they are the third most common
cause of bacterial gastroenteritis (Tam et al., 2012). Although
NTS symptoms are often limited to the gastrointestinal tract,
invasive disease can occur, especially in high-risk groups such
as immunocompromised patients and the elderly (Parry et al.,
2013). Invasive disease has also been observed in several low-
income settings (Kingsley et al., 2009; Feasey et al., 2016; Ashton
et al., 2017) and was estimated to result in 3.4 million cases and
681,000 deaths worldwide in 2010, with the heaviest burden on
the African continent (Ao et al., 2015).
While the use of antimicrobial agents to treat invasive
and severe gastrointestinal cases has decreased mortality rates
for NTS infections, and veterinary antimicrobial therapy has
lowered the risk of zoonoses, these interventions have come
with a price. Increased use of the traditional first-line drugs
ampicillin, chloramphenicol, streptomycin, sulphonamides and
tetracycline quickly led to the emergence of ACSSuT-type
S. enterica serovar Typhimurium strains in the 1980s, resistant
to exactly these drugs (Threlfall et al., 1996; Boyd et al.,
2002). Resistance to fluoroquinolones, introduced to circumvent
this problem, developed as a consequence of the veterinary
use of enrofloxacin (Threlfall et al., 1997). NTS strains
resistant to extended-spectrum cephalosporins, an alternative
to fluoroquinolones for the treatment of invasive disease, have
been detected throughout Europe since the 1990s (Tassios
et al., 1999; Villa et al., 2002; Burke et al., 2014). By 2015,
29.3% of the NTS isolates in the European Union were
categorized as multidrug-resistant (MDR) (EFSA, 2017). More
recently, the spread of an extensively drug-resistant strain
of S. Kentucky, non-susceptible to ciprofloxacin, extended-
spectrum cephalosporins, carbapenems, most aminoglycosides,
trimethoprim-sulfamethoxazole, and azithromycin, has sparked
concern (Le Hello et al., 2013). Resistance to azithromycin
has been reported in other NTS serovars (Villa et al., 2015;
Nair et al., 2016). Acquired resistance to colistin, considered
the antimicrobial of last resort for the treatment of many
MDR Gram-negative pathogens, has also been detected in NTS
(Doumith et al., 2016).
Due to the association of MDR NTS infection with
increased mortality and higher costs to the healthcare system,
determination of antimicrobial resistance (AMR) profiles is an
essential part of NTS surveillance in reference laboratories.
Phenotypic serotyping and phage typing at Public Health
England’s (PHE) Gastrointestinal Bacteria Reference Unit
(GBRU) has been replaced by the routine implementation
of whole genome sequencing (WGS) for identification and
surveillance of Salmonella since April 2014 (Ashton et al.,
2016). As well as providing information about phylogenetic
relationships between isolates, the sequencing data can be used
to identify resistance determinants and therefore constitutes a
rapid alternative to monitor emerging trends in AMR patterns
of NTS. With this study, we sought to evaluate the suitability
of inferring AMR profiles from genotype in NTS in comparison
with traditional phenotypic susceptibility testing.
MATERIALS AND METHODS
Bacterial Isolates
Between April 2014 and March 2015, PHE received 7,009
NTS S. enterica subspecies enterica isolates for surveillance
purposes. After deduplication of outbreak cases and exclusion of
isolates with WGS of insufficient quality, results of phenotypic
susceptibility testing and genotypic profiling were available for
3,491 isolates (49.81%). These comprised 227 different serovars
plus 66 isolates that could not successfully be subtyped to serovar
level. GBRU’s routine phenotypic testing strategy for surveillance
of NTS attempts to maximize the detection of AMR by focussing
on serovars known to have high resistance rates. This leads to
an under-representation of some serovars, such as S. Enteritidis,
and an over-representation of others, such as S. Infantis and
S. Kentucky, in this dataset. Amongst the isolates included in the
analysis, the ten most common serovars were S. Typhimurium
(23.69%, n = 827), S. Enteritidis (8.42%, n = 294), S. Virchow
(4.01%, n = 140), S. Stanley (3.98%, n = 139), S. Newport (3.75%,
n = 131), S. Infantis (3.47%, n = 121), S. Kentucky (3.12%,
n = 109), S. Oranienburg (2.06%, n = 72), S. Java (2.03%, n = 71)
and S. Saint-Paul (1.78%, n = 62). The majority (n = 3487) of
isolates were of human origin, three were derived from food and
one from an unknown source.
Whole Genome Sequencing
Sequencing libraries were prepared from extracted genomic DNA
using the Nextera XT DNA Sample Preparation kit (Illumina,
Cambridge, United Kingdom). Short-read sequence fragments of
100 bp were produced by paired-end sequencing on an Illumina
HiSeq platform (Illumina, Cambridge, United Kingdom). FASTQ
sequences were deposited in the NCBI Short Read Archive
under the BioProject PRJNA315192. Short read archive accession
numbers are available in Supplementary Table S1.
Serovar Prediction
Serovars were inferred from the sequencing data using the seven-
gene MLST and eBurst Group approach (Achtman et al., 2012;
Ashton et al., 2016). Traditional serotyping was not performed.
Detection of Antimicrobial Resistance
Determinants
For the identification of AMR determinants, the ‘Genefinder’
algorithm was employed, which maps the sequencing reads to a
set of reference sequences using Bowtie 2 followed by generation
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of an mpileup file using Samtools (Langmead and Salzberg,
2012). To establish the presence of the reference sequence or
nucleotide variations within the read set, a positive match had
to meet the following criteria: query coverage 100%, base-call
variation > 85% and nucleotide identity > 90%.
The reference database used included acquired genes and
mutations known to confer resistance to β-lactams (including
penicillins, 2nd-, 3rd- and 4th-generation cephalosporins
and carbapenems), fluoroquinolones, aminoglycosides,
sulphonamides, tetracyclines, trimethoprim and phenicols
(Day et al., 2017b; Sadouki et al., 2017). Variants of
β-lactamase genes were identified with 100% identity
based on reference sequences downloaded from the Lahey1
or NCBI β-lactamase data resources2. Further reference
sequences for acquired resistance genes were obtained from
the Comprehensive Antimicrobial Resistance Database3
and the Resfinder datasets4. Chromosomal mutations
were limited to previously published variations within the
quinolone resistance-determining regions (QRDRs) of gyrA
and parC.
Antimicrobial Susceptibility Testing
Isolates were recovered from the PHE archive and retrospective
susceptibility testing was performed and interpreted using
EUCAST breakpoints and screening concentrations5. For the
purpose of epidemiologically screening the large numbers of
S. enterica isolates received by the reference laboratory, agar
dilution with Mueller–Hinton agar was used to determine
breakpoint values of ampicillin, cefotaxime, ceftazidime,
cefpirome, ertapenem, chloramphenicol, gentamicin,
streptomycin, tobramycin, sulphonamides, tetracycline,
trimethoprim and ciprofloxacin. Decreased susceptibility
(MIC 0.06–0.25 mg/L) and resistance (MIC > 0.5 mg/L)
were distinguished for ciprofloxacin. If required, MICs
were confirmed by Etest R© (bioMérieux, Marcy-l’Étoile,
France) or by agar dilution. To aid detection of OXA-48-
like carbapenemases and acquired AmpC genes, breakpoint
testing of temocillin and cefoxitin, respectively, was included in
the panel.
Statistical Analysis
Comparisons were made between the prevalence of resistance
determinants associated with isolates, for which a travel
history was available, and those for which there was no
information about recent travel. Travel destinations were
grouped according to the United Nations geoscheme.
Statistical significance was assessed using the chi-square test.
A p-value ≤ 0.05 was considered statistically significant.
Statistical analysis was performed using R’s chisq.test
function.
1www.lahey.org
2https://www.ncbi.nlm.nih.gov/pathogens/beta-lactamase-data-resources
3http://arpcard.mcmaster.ca
4https://cge.cbs.dtu.dk/services/data.php
5http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_
tables/v_8.0_Breakpoint_Tables.pdf
RESULTS
Comparison Between Phenotypic and
Genotypic AMR Profiles
Phenotypic and genotypic AMR profiling was highly correlated,
with the profiles of 3,415 isolates (97.82%) being entirely in
agreement for both approaches for all 15 antimicrobials from
nine different classes. For the 76 isolates with discordant
results, the genotype wrongly predicted pan-susceptibility for one
isolate (1.32%). This isolate was phenotypically resistant to one
antimicrobial. For a further 64 discrepant isolates (84.21%), the
mismatch was based on false or missing prediction of resistance
to a single antimicrobial, and for 11 (14.47%) based on two
antimicrobials.
Overall, 88 (0.17%) out of a possible 52,365
isolate/antimicrobial combinations did not match (Table 1).
Of these discrepant results, 69/88 (78.41%) constituted major
errors (MEs), i.e., isolates were genotypically predicted to be
resistant but showed phenotypic susceptibility, rather than very
major errors (VMEs), which were genotypically susceptible
but phenotypically resistant. The largest fraction of the 88
mismatches could be attributed to streptomycin (n = 59, 67.05%),
51 of these were MEs. Sensitivity of resistance prediction from
genotype was ≥95% for all antimicrobials except temocillin.
However, only a single isolate was found to be phenotypically
resistant to temocillin. Specificity of prediction exceeded 98% for
all fifteen antimicrobials tested.
Resistance to β-lactams
Of the 3,491 isolates in this study, 749 (21.46%) carried genes
conferring resistance to β-lactam antibiotics (Supplementary
Table S2). The most common genes were the penicillinase-
encoding blaTEM−1 (n = 603) and blaPSE−1/blaCARB−2 (n = 75).
Additionally, other TEM-type β-lactamase genes were detected in
36 isolates, including blaTEM−117 (n = 12) and blaTEM−135 (n = 7).
The single ME associated with predicted ampicillin resistance
was due to the presence of blaTEM−1 without phenotypic
consequences. Seven isolates (0.20%) carried OXA-type class D
β-lactamases. Of these, four were found in S. Typhimurium and
two in S. Kentucky.
Genes for CTX-M-type extended-spectrum β-lactamases
(ESBLs) were present in 41 isolates (1.17%), most commonly
blaCTX−M−9 (n = 10) and blaCTX−M−55 (n = 9). Twenty of these
were S. Typhimurium and five S. Kentucky. Additionally, four
isolates carried the blaSHV−12 ESBL gene. No ESBL genes were
detected in S. Enteritidis. Combinations of penicillinase and ESBL
genes occurred in 16 isolates, most frequently blaTEM−1 with
blaCTX−M−55 (n = 9).
Sixteen isolates (0.46%), seven of these S. Typhimurium
and one S. Kentucky, had the acquired AmpC resistance gene
blaCMY−2. Carbapenemase genes were not detected.
Resistance to Quinolones
Multiple mutations in the QRDR of the DNA gyrase subunit
gene gyrA in combination with multiple mutations in the DNA
topoisomerase gene parC are expected to confer full ciprofloxacin
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TABLE 1 | Comparison of phenotypic antimicrobial susceptibility testing and genome-derived resistance prediction for non-typhoidal Salmonella enterica (n = 3491).
Antimicrobial Phenotype: susceptible Phenotype: resistant Sensitivity (%) Specificity (%)
Genotype: resistant Genotype: susceptible Genotype: resistant Genotype: susceptible
Ampicillin 1 2742 747 1 99.87 99.96
Temocillin 0 3490 0 1 0 100
Cefoxitin 0 3471 19 1 95.0 100
Cefotaxime 0 3434 57 0 100 100
Ceftazidime 0 3444 47 0 100 100
Cefpirome 0 3444 47 0 100 100
Ertapenem 0 3481 10 0 100 100
Chloramphenicol 4 3284 201 2 99.01 99.88
Gentamicin 1 3351 138 1 99.28 99.97
Streptomycin 51 2821 613 8 98.71 98.22
Tobramycin 2 3392 97 0 100 99.94
Sulphonamides 2 2661 828 0 100 99.92
Tetracycline 6 2568 917 0 100 99.77
Trimethoprim 1 3185 301 4 98.69 99.97
Ciprofloxacin 1 3352 137 1 99.28 99.97
Values shown designate the number of isolates. For ciprofloxacin only isolates with a MIC > 0.5 mg/L are shown.
resistance (MIC > 0.5 mg/L) and were observed in 82 isolates
(2.35%) (Table 2). The most common combinations were either
gyrA[83:S-F;87:D-Y] (n = 41) or gyrA[83:S-F;87:D-N] (n = 25) in
conjunction with parC[57:T-S;80:S-I]. For S. Kentucky, multiple
QRDR mutations were identified in 77 isolates. Neither S.
Typhimurium nor S. Enteritidis had any of these mutations
(Supplementary Table S2).
A further 599 isolates (17.16%) harbored determinants
responsible for reduced susceptibility to ciprofloxacin (MIC
0.06–0.25 mg/L) with or without parC mutations. These
included a single gyrA mutation in the QRDR (n = 430),
most commonly gyrA[87:D-Y] (n = 155) or gyrA[83:S-Y]
(n = 112) and/or one or multiple plasmid-mediated quinolone
resistance (PMQR) genes (n = 195). The most frequent PMQR
genes detected were qnrS1 (n = 95) and qnrB19 (n = 49).
PMQR genes were rare in S. Kentucky (n = 1 compared with
n = 188 for chromosomal mutations). One or more PMQR
determinants in combination with a single gyrA mutation
were found in twenty isolates. Of the isolates carrying both
multiple parC and gyrA mutations, only one S. Indiana had
additional PMQR genes, namely the eﬄux pump-encoding oqxA
and oqxB.
Seven isolates carried the fluoroquinolone- and
aminoglycoside-modifying N-acetyltransferase gene variant
aac(6′)-Ib-cr, six of these in combination with other quinolone
resistance determinants. Of the 138 isolates showing full
ciprofloxacin resistance, nineteen carried a single gyrA
mutation only, 17 a single gyrA mutation together with a
PMQR gene, 20 had one or more PMQR genes and a single
isolate carried parC[57:T-S] only (Table 2). The single ME
associated with predicted ciprofloxacin resistance was based
on the presence of gyrA[83:S-F;87:D-N] and parC[57:T-
S;80:S-I] resulting in reduced susceptibility instead of full
resistance.
Resistance to Aminoglycosides
Genes predicted to confer resistance to streptomycin were
detected in 728 isolates (20.85%): 436 had strA-strB only and
292 carried genes encoding aminoglycoside adenylyltransferases,
most commonly aadA2 (n = 189) and aadA17 (n = 107)
(Supplementary Table S2). Both strA-strB and an aadA variant
were observed in 101 isolates. Of the 51 MEs associated with
streptomycin resistance, 27 were due to the presence of strA-
strB and twelve had aadA2 and aadA17 without phenotypic
consequences.
All but eight of the total 3,491 isolates carried an
aminoglycoside acetyltransferase aac(6′)-type gene. However,
the majority either had the aac(6′)-Iy (n = 1997), more common
in S. Enteritidis (n = 297), or aac(6′)-Iaa variant (n = 1486), more
common in S. Typhimurium (n = 869) and S. Kentucky (n = 81).
Of the 2,726 isolates carrying either of these two genes as the
only aminoglycoside resistance determinant, only eleven showed
phenotypic resistance to an aminoglycoside antimicrobial.
Aminoglycoside acetyltransferase aac(3) variants associated
with resistance to gentamicin and tobramycin were detected
in 130 isolates (3.72%), most notably aac(3)-Id (n = 50) and
aac(3)-IIa (n = 36). aac(3)-IVa, which confers resistance to the
veterinary aminoglycoside apramycin, was present in 24 isolates.
No aac(3) variants were found in S. Enteritidis. Furthermore,
the aminoglycoside adenylyltransferase gene ant(2′′)-Ia (n = 12)
and the aminoglycoside phosphotransferase genes aph(4)-Ia
(n = 23) and aph(3′)-IIa (n = 10) were identified. None
of these were present in S. Enteritidis or S. Kentucky. No
16S rRNA methyltransferase genes were detected. In the
single isolate predicted to be resistant to gentamicin but
showing phenotypic susceptibility, aac(3)-IId was observed. For
prediction of tobramycin resistance, one ME was associated
with the presence of ant(2′′)-Ia and the second one with
aac(3)-IIa.
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TABLE 2 | Relationship between decreased ciprofloxacin susceptibility (<CIP, MIC 0.06–0.25 mg/L), full ciprofloxacin resistance (>CIP, MIC > 0.5 mg/L) and the most
common genotypic quinolone resistance determinants in non-typhoidal Salmonella enterica.
Number of isolates Phenotype Genotype
<CIP >CIP
S R S R
116 6 110 114 2 gyrA[87:D-Y]
51 1 50 42 9 gyrA[83:S-Y];parC[57:T-S]
51 4 47 51 0 gyrA[87:D-N]
47 0 47 43 4 gyrA[83:S-Y]
44 0 44 39 5 parC[57:T-S];qnrS1
41 0 41 0 41 gyrA[83:S-F;87:D-Y];parC[57:T-S;80:S-I]
37 1 36 28 9 qnrS1
34 2 32 34 0 gyrA[87:D-Y];parC[57:T-S]
32 0 32 31 1 parC[57:T-S];qnrB19
29 1 28 28 1 gyrA[83:S-F];parC[57:T-S]
25 0 25 1 24 gyrA[83:S-F;87:D-N];parC[57:T-S;80:S-I]
23 0 23 20 3 gyrA[83:S-F]
19 2 17 19 0 gyrA[87:D-G]
17 2 15 17 0 gyrA[87:D-G];parC[57:T-S]
12 6 6 12 0 parC[57:T-S];qnrD
12 0 12 9 3 qnrB19
11 0 11 0 11 gyrA[83:S-F;87:D-G];parC[57:T-S;80:S-I]
11 0 11 11 0 gyrA[87:D-N];parC[57:T-S]
8 0 8 8 0 qnrA1
7 1 6 3 4 aac(6′)-Ib-cr
4 0 4 0 4 gyrA[83:S-Y];parC[57:T-S];qnrS1
4 0 4 0 4 gyrA[87:D-Y];qnrS1
4 0 4 4 0 parC[57:T-S];qnrB9
4 0 4 4 0 parC[57:T-S];qnrS2
4 0 4 2 2 qnrB6
3 0 3 0 3 gyrA[83:S-F;87:D-G];parC[57:T-S;80:S-R]
3 0 3 1 2 gyrA[83:S-Y];parC[57:T-S];qnrD
3 0 3 0 3 gyrA[83:S-Y];qnrS1
2 0 2 2 0 parC[57:T-S];qnrA1
2 0 2 2 0 parC[57:T-S];qnrB1
Values shown are the number of isolates. S, susceptible; R, Resistant.
Resistance to Sulphonamides,
Tetracyclines and Trimethoprim
Sulphonamide resistance genes were found in 830 isolates
(23.78%): 490 carried sul2, 350 sul1 and 75 sul3 (Supplementary
Table S2). Seventy-seven isolates had a combination
of two different sul genes, most notably sul1 and sul2
(n = 37), and four isolates carried all three variants.
Of the two MEs that occurred for the prediction of
sulphonamide resistance, one was based on the presence of
sul2 and one on the presence of sul1 without phenotypic
consequences.
Tetracycline resistance genes occurred in 927 isolates
(26.55%), mostly tet(A) (n = 843). Additional, less frequently
encountered genes were the eﬄux pump-encoding tet(G)
(n = 68), tet(C) (n = 10) and tet(D) (n = 5), and the ribosomal
protection protein-producing tet(M) (n = 57). Fifty-six isolates
carried a combination of two different genes, mainly tet(A) and
tet(M) (n = 51). Five of the six isolates with predicted but not
phenotypic tetracycline resistance harbored tet(M).
Trimethoprim resistance-conferring dfrA gene variants
were identified in 302 isolates (8.65%), most commonly
dfrA12 (n = 84), dfrA1 (n = 81) and dfrA14 (n = 65).
The remaining isolates carried eight additional variants
of dfrA. Only one isolate harbored a combination of
two different genes (dfrA1;dfrA12). The single ME
associated with prediction of trimethoprim resistance
was due to the presence of dfrA14 without phenotypic
consequences.
Resistance to Phenicols
Genes linked to chloramphenicol resistance were identified in
215 isolates (6.16%) (Supplementary Table S2). Eﬄux pump
genes were found in 194 isolates: floR (n = 147) and/or
cmlA1 (n = 67). All four MEs were associated with the
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presence of cmlA1. Chloramphenicol acetyltransferase genes of
the catA- or catB-type were detected in 32 isolates. Eleven
isolates harbored genes encoding both an eﬄux pump and an
acetyltransferase.
Multidrug Resistance
Out of a total 3,491 isolates, 1,301 (37.27%) were phenotypically
resistant to at least one antimicrobial of the testing panel
(Table 3). For the two most common serovars, S. Typhimurium
and S. Enteritidis, this applied to 568/827 (68.68%) and 130/294
(44.22%) isolates, respectively, and for S. Kentucky to 82/109
isolates (75.23%).
MDR, i.e., resistance to three or more antimicrobial classes,
was observed in 848 of all the NTS isolates (24.29%), 467
S. Typhimurium (56.47%), 70 S. Kentucky (64.22%) and only
13 S. Enteritidis (4.42%). One S. Typhimurium isolate exhibited
resistance to all nine antimicrobial classes tested.
Detected in 231 isolates overall (6.62%), resistance to
ampicillin, streptomycin, sulphonamides and tetracyclines was
the most commonly occurring MDR profile, all but one isolate
were S. Typhimurium. In 219 isolates with this profile, the
underlying genotype was blaTEM−1, strA-strB sul2, tet(A). For
S. Enteritidis, decreased susceptibility to ciprofloxacin was
observed most frequently (n = 87) with gyrA[87:D-Y] being the
TABLE 3 | Most common combinations of antimicrobial resistance phenotypes and genotypes in non-typhoidal Salmonella enterica for all serovars, S. Typhimurium and
S. Enteritidis.
Serovar Antimicrobial
classes
Number of
isolates (%)
Most common
phenotypic combination
(number of isolates)
Most common
genotypic combination
(number of isolates)
Total (n = 3491) 0 2190 (62.73) – –
1/2 453 (12.98) <CIP (196) gyrA[87:D-Y] (52)
3/4 514 (14.72) AMP/STR/SUL/TET (231) sul2;strA-
strB;tet(A);blaTEM−1 (219)
5/6/7 315 (9.02) AMP/CHL/STR/SUL/TET (37) sul1;tet(G);aadA17;aadA2;floR;
blaPSE−1/blaCARB−2(30)
8/9 19 (0.54) AMP/CAZ/CHL/<CIP/CPR/CTX/ETP/
FOX/GEN/STR/SUL/TET/ TMP/TOB (1)
qnrS1;sul1;sul2;sul3;strA-
strB;tet(M);tet(A);dfrA12;aac(3)-
Iva;aadA2;aadA12;aph(4)-
Ia;cml1;floR;blaCMY−2;blaTEM−1 (1)
S. Typhimurium
(n = 827)
0 259 (31.32) – –
1/2 101 (12.21) TET (40) tet(A) (38)
3/4 317 (38.33) AMP/STR/SUL/TET (230) sul2;strA-
strB;tet(A);blaTEM−1 (220)
5/6/7 138 (16.69) AMP/CHL/STR/SUL/TET (33) sul1;tet(G);aadA17;aadA2;floR;
blaPSE−1/blaCARB−2(28)
8/9 12 (1.45) AMP/CAZ/CHL/<CIP/CPR/CTX/ETP/
FOX/GEN/STR/SUL/TET/ TMP/TOB (1)
qnrS1;sul1;sul2;sul3;strA-
strB;tet(M);tet(A);dfrA12;aac(3)-
Iva;aadA2;aadA12;aph(4)-
Ia;cml1;floR;blaCMY−2;blaTEM−1 (1)
S. Enteritidis
(n = 294)
0 164 (55.78) – –
1/2 117 (39.80) <CIP (87) gyrA[87:D-Y] (24)
≥3 13(4.42) AMP/<CIP/STR/SUL/TET (4) gyrA[87:D-N];sul2;strA-
strB;tet(A);blaTEM−1 (3)
S. Kentucky
(n = 109)
0 27 (24.77) – -
1/2 12 (11.01) AMP/> CIP (5) gyrA[83:S-F;87:
D-Y];parC[57:T-S;80:
S-I];blaTEM−1 (4)
3/4 19 (17.43) AMP/> CIP/SUL/TET (11) gyrA[83:S-F;87:
D-Y];parC[57:T-S;80:
S-I];sul1;tet(A);aadA7;blaTEM−1 (3)
5/6/7 51 (46.79) AMP/> CIP/GEN
/STR/SUL/TET (24)
gyrA[83:S-F;87:
D-Y];parC[57:T-S;80:
S-I];sul1;tet(A);aac(3)-
Id;aadA7;blaTEM−1 (20)
AMP, ampicillin; FOX, cefoxitin; CTX, cefotaxime; CAZ, ceftazidime; CPR, cefpirome; ETP, ertapenem; CHL, chloramphenicol; GEN, gentamicin; STR, streptomycin; TOB,
tobramycin; SUL, sulphonamides; TET, tetracycline; TMP, trimethoprim; <CIP, ciprofloxacin MIC 0.06–0.25 mg/L; >CIP, ciprofloxacin MIC > 0.5 mg/L. Values in the
column antimicrobial class denote the numbers of antimicrobial classes the isolates are resistant to.
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most common genotypic determinant (n = 24). The majority of
resistant S. Kentucky showed phenotypic resistance to ampicillin,
ciprofloxacin, gentamicin, streptomycin, sulphonamides and
tetracyclines (n = 24). In 20 isolates, this profile was based
on the presence of blaTEM−1, gyrA[83:S-F;87:D-Y], parC[57:T-
S;80:S-I], aac(3)-Id, aadA7, sul1 and tet(A) (n = 20). Thirty-three
S. Typhimurium isolates (3.99%) exhibited the penta-resistant
phenotype with resistance to ampicillin, chloramphenicol,
streptomycin, sulphonamides and tetracyclines. Of these, 28
carried a combination of blaPSE−1/blaCARB−2, floR, aadA17,
aadA2, sul1 and tet(G).
AMR and International Travel
Travel history data was available for 1,070 isolates (30.65%)
(Supplementary Table S3). The proportion of isolates resistant
to at least one antimicrobial of the testing panel was significantly
higher for isolates known to be travel-associated (p = 4.5× 10−5)
(Figure 1). MDR, on the other hand, was correlated with travel
to specific regions, namely Eastern Africa (p = 0.04), North
Africa (p = 0.005), Western Africa (p = 0.03), Southeast Asia
(p = 3.4× 10−5) and the Caribbean (p = 1.3× 10−4). ESBL genes
were more likely to be found in isolates related to travel to North
Africa (p = 0.01) and South America (p = 0.03). Mutations and
acquired genes conferring decreased susceptibility or resistance
to ciprofloxacin were more likely to occur in travel-associated
isolates (resistance-conferring mutations: p = 8.5 × 10−6; single
gyrA mutations: p = 4.5 × 10−9; PMQRs: p = 1.3 × 10−7).
The presence of genes conferring ciprofloxacin resistance was
associated with travel to Southern Asia (p = 5.6 × 10−6).
Determinants of aminoglycoside resistance were more prevalent
in travel-related isolates, particularly for travel destinations
in North Africa, Asia and the Caribbean. The presence of
sulphonamide and tetracycline resistance genes was linked to
travel to Southeast and Western Asia and the Caribbean while
dfrA genes were commonly found in isolates associated with
travel to North Africa (p = 5.2× 10−7) and South Asia (p = 0.01).
Furthermore, travel to North Africa or Southeast Asia was a
risk factor for acquisition of isolates carrying chloramphenicol
resistance genes (p = 0.009 and p = 4.7× 10−10, respectively).
DISCUSSION
The implementation of WGS for surveillance of enteric
pathogens has revolutionized the work of public health
laboratories, as it allows inference of a multitude of pathogen
characteristics in a single sequencing run, which would
traditionally require a series of independent laboratory tests.
A prominent example of the added value provided by WGS is the
generation of AMR profiles from the sequences in real-time.
WGS has previously proven successful for prediction of AMR
profiles in a variety of gastrointestinal pathogens, including
Shigella sonnei (Sadouki et al., 2017), Escherichia coli (Stoesser
et al., 2013; Tyson et al., 2015; Day et al., 2017a), S. Typhi
(Day et al., 2017b) and smaller datasets of NTS (Zankari et al.,
2013; Nair et al., 2016; McDermott et al., 2016). Our present
comparison of phenotypic susceptibility testing and genotypic
prediction of AMR profiles based on WGS data for a much larger
dataset, comprising 3,491 NTS isolates, identified 88 discordant
results (0.17%) out of a possible 52,365 isolate/antimicrobial
combinations, with the AMR profiles of 3,415 isolates (97.82%)
completely matching for both approaches. Zankari et al. (2013)
observed complete agreement of the two approaches for fifty
S. Typhimurium isolates but only when excluding ciprofloxacin
from the testing panel. Similar to our results, McDermott et al.
(2016) found lower sensitivity and specificity for prediction of
streptomycin resistance than for other antimicrobials tested.
Despite being an invaluable tool for surveillance purposes,
AMR prediction based on WGS data is not yet deemed
suitable to guide treatment choices (Ellington et al., 2017).
Many MEs, where an isolate is phenotypically susceptible but
carries genetic resistance determinants, seem to be associated
with the breakpoints used for phenotypic testing. In some
cases, the MICs are just below the recommended breakpoints
but slight technical variations of the agar dilution method
are possible so that the isolate would be falsely classified as
susceptible. This seems to be an issue especially when testing
for streptomycin resistance (Garcia-Migura et al., 2012), which
would explain the relatively large number of mismatches in
the present study. Recently, it has been suggested to adapt the
breakpoint values to take into account MICs associated with
the presence of specific resistance determinants (Tyson et al.,
2017). Additionally, many of the resistance genes detected by
the algorithm are plasmid-encoded but phenotypic susceptibility
testing was carried out retrospectively. During storage and sub-
culture of the isolates plasmids may be lost. Thus, genes detected
during sequencing after initial cultivation might not be present
when retrospective phenotypic testing is performed on a different
colony. Furthermore, silent resistance genes, such as blaCMY−2
and tet variants, have been observed previously in Salmonella
(Heider et al., 2009; Adesiji et al., 2014). Other genes, such
as the aac(6′) variants, are normally silent and only become
transcriptionally active in rare cases (Magnet et al., 1999).
The other mismatch category, the VMEs, where an isolate is
genotypically predicted to be susceptible but exhibits phenotypic
resistance, highlight the importance of active curation of
the resistance gene database used for genotypic prediction.
Mismatches are likely based on the presence of resistance
determinants not included in the reference database used for
prediction or on novel, unknown resistance mechanisms, the
genetic determinants of which have not yet been described.
Our pipeline, for instance, does not detect impermeability or
eﬄux pump genes potentially contributing to ciprofloxacin
resistance (Hopkins et al., 2005). Continuous scanning for new
research findings should be carried out to enable identification
of novel resistance mechanisms. These novel mechanisms will
then be incorporated into the reference databases to maintain a
high level of prediction sensitivity. Only recently, for example,
computational methods identified previously unknown qnr-type
fluoroquinolone resistance genes (Boulund et al., 2017). Despite
these issues, the overall ME and VME rates of 0.13 and 0.04%,
respectively, obtained in this study fall below the cut-offs of 3 and
1.5% from the US Food and Drug Administration for authorizing
new susceptibility testing devices (FDA, 2009).
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FIGURE 1 | Association of resistance determinants and travel history. Red cells indicate a significant association (p-value < 0.05) between patient travel and the
occurrence of phenotypic resistance to at least one antimicrobial, multidrug resistance (MDR) or the presence of specific resistance determinants. gyrA denotes
isolates with single mutations in the gene responsible for reduced ciprofloxacin susceptibility. Only travel destinations for which there was an association with at least
one resistance determinant are shown. PMQR, plasmid-mediated quinolone resistance; CHL, chloramphenicol.
Specificity and sensitivity of ciprofloxacin resistance
prediction exceeded 99% but we only considered isolates
with an MIC > 0.5 mg/L for this evaluation. Traditionally, gyrA
mutations in combination with parC mutations were thought to
be required for ciprofloxacin resistance (Ruiz et al., 1997) and
PMQRs on their own were not considered sufficient. Indeed,
in our study, the majority of isolates showing resistance carried
at least two mutations in both gyrA and parC. Thirty-seven
had a PMQR gene, alone or in conjunction with a single gyrA
mutation, which would normally be expected to result in reduced
susceptibility instead of full resistance. Ciprofloxacin MICs
for isolates carrying PMQR genes alone were found to range
between 0.25 and 1 mg/L (Garcia-Fernandez et al., 2009) so
that some isolates with this profile would be classed as resistant
and some as having reduced susceptibility during phenotypic
testing. Although the QRDR of gyrA is located between amino
acids 67 and 106, mutations at positions 83 and 87 are most
common (Yoshida et al., 1990). In our study, none of the isolates
with mutations at other positions of the QRDR alone exhibited
reduced ciprofloxacin susceptibility.
It has been suggested previously that an increased use of
alternative antimicrobials, such as ciprofloxacin and extended-
spectrum β-lactams, favored the re-emergence of susceptibility
to classical first-line drugs (Sood et al., 1999; Rahman et al.,
2002). The limitation of our study was that it was biased
toward serovars selected for their known high resistance rates,
and therefore not a true representation of the expected serovar
distribution in England and Wales over this time frame. We were
therefore unable to assess changes in incidence of resistance to
specific antimicrobials over the years. However, moving forward,
genome-derived AMR profiling will provide a robust framework
to explore longitudinal trends.
A worrying trend is the increase in resistance to extended-
spectrum cephalosporins (Su et al., 2005; Mataseje et al.,
2009). Since these antimicrobials are used as an alternative for
treatment of invasive disease in case of resistance to ciprofloxacin,
the emergence of co-resistance to both antimicrobial classes
is of great concern. Co-resistance is especially prevalent
in Asia (Lee et al., 2009) and was identified in thirteen
isolates (0.37%) in this study, a slight increase from the
0.25% prevalence observed in the UK between 2010 and
2012 (Burke et al., 2014). Seven of the eighteen isolates
carrying CTX-M-type ESBLs were associated with travel to
Asia and a further seven with travel to North Africa.
Similarly, as observed previously (Hopkins et al., 2007),
PMQR genes were more likely to be found in isolates from
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patients who had traveled to Asia. Extensively drug-resistant
S. Typhimurium, like the one isolate in this study resistant
to all eleven antimicrobial classes tested, have been found in
Southeast Asia before (Benacer et al., 2010; Vo et al., 2010).
Unfortunately, no travel history data was available for this
isolate.
In addition to providing information on AMR for the
entire NTS population, WGS-based prediction was able to
highlight some interesting genotypic differences between the
most common serovars S. Typhimurium and S. Enteritidis
and the extensively drug-resistant S. Kentucky: ESBL genes
and aac(3) variants, while found in S. Typhimurium and S.
Kentucky, were absent in S. Enteritidis. Only S. Kentucky
carried multiple mutations in the QRDRs of gyrA and parC but
PMQR genes were less common than in other serovars. A more
detailed investigation of these differences might lead to a better
understanding of the varying outcomes associated with infections
caused by different serovars of NTS (Jones et al., 2008).
CONCLUSION
This large-scale study supports the suitability of WGS-based
prediction to reliably replace phenotypic susceptibility testing for
rapid monitoring of emerging trends in AMR patterns in NTS
and for studying the spread of AMR genes in this pathogen
population. Since sequencing is routinely used in public health
laboratories already, it constitutes a time-saving alternative to
traditional approaches that can further our understanding of
resistance mechanisms as long as constant curation of the
resistance gene database used is warranted. Prediction for further
antimicrobials such as macrolides, fosfomycin and colistin will
be validated in the near future to increase the robustness of the
pipeline. Information derived from WGS-based studies can then
be used to inform public health interventions aimed at limiting
further dissemination of AMR genes and thus aid in the fight
against the global AMR threat.
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